FPHAX Mutual Fund

NAV$32.66

Fund Essentials - as of Feb 28, 2026

Net Assets
$703M
Expense Ratio
0.67%
Dividend Yield (Current)
5.09%
Holdings
60
Inception Date
Jun 18, 2001
Fund Family
Fidelity Investments (US)
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Semi-Annually

Performance

YTD+9.10%
1 Year+44.58%
3 Year+18.50%
5 Year+14.22%
10 Year+12.30%

Asset Allocation

Stocks: 95.47%
Bonds: 0.08%
Cash: 4.39%
Other: 0.07%

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co25.18%
GSKGlaxosmithkline Finance Plc10.07%
JNJJohnson & Johnson7.53%
UCB:BRUcb Sa5.01%
AZN:LNAstraZeneca PLC4.93%
Top 10 Concentration: 75.56%Report Date: Feb 28, 2026
Download all 60 holdings for FPHAX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
5.09%
Frequency
Semi-Annually
Latest Distribution
$1.86
-

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

FPHAX Mutual Fund Overview

FPHAX Mutual Fund (Fidelity Select Pharmaceuticals Portfolio) is managed by Fidelity Investments (US) with $702.6M in net assets. FPHAX expense ratio is 0.67%, holding 60 positions across sectors including Health Care, Unknown, Financials. Inception date: 2001-06-18.

FPHAX performance shows a YTD return of 9.10%. The 1-year return is 44.58% and the 5-year return is 14.22%. FPHAX dividend yield stands at 5.09%, paid semi-annually.

FPHAX top holdings include Eli Lilly & Co (25.2%), Glaxosmithkline Finance Plc (10.1%), Johnson & Johnson (7.5%), Ucb Sa (5.0%), AstraZeneca PLC (4.9%). View all FPHAX holdings, sector breakdown, or dividend history.

FPHAX can be compared against other funds using the overlap calculator or side-by-side comparison tool. FPHAX alternatives are available via the screener, along with tax-loss harvesting opportunities.